OTC RiVive™ – A Compassionate Overdose Response™
Learn How to Use RiVive
No company, entity, or individual will profit from sales of RiVive.
RiVive Naloxone HCI Nasal Spray 3 mg is an FDA-approved compassionate dose naloxone product that’s available over-the-counter (OTC). It’s intended for the emergency treatment of opioid overdose and is manufactured right here in the United States. According to the CDC, naloxone is a safe and effective life-saving medication that can reverse an opioid overdose—including heroin and fentanyl.
RiVive uses a novel OTC intranasal formulation of naloxone delivered as an atomized spray (0.1 ml) that can save lives. It uses an easy-to-use standard unit dose system for single administration for the emergency treatment of opioid overdose without a prescription. RiVive’s 3 mg formulation produces a 3-fold higher systemic exposure with comparable early absorption to the reference naloxone product (0.4 mg delivered via intramuscular injection), as well as robust human factors work demonstrating that laypeople are able to administer RiVive in a simulated emergency overdose situation.
HRT is able to sell RiVive at a low price thanks to our status as the only 501(c)(3) non-profit pharmaceutical company selling naloxone. Our manufacturing cost is our price, we make zero profit on RiVive. This allows us to strive for our mission: SAVING AS MANY LIVES AS POSSIBLE THAT WOULD OTHERWISE BE LOST TO OPIOID OVERDOSE
Warning: when using this product, some people may experience symptoms when they wake up such as shaking, sweating, nausea, or feeling angry.
Harm Reduction Therapeutics – A Unique Nonprofit Pharma Company
As a 501(c)(3) nonprofit pharmaceutical company, you can join our mission to save lives that would have otherwise been lost to opioid overdose.
We are seeking funding partners to sustain manufacturing operations and broaden distribution.
Funders can direct their financial support to further lowering the price of RiVive, making more of it available free of charge to specific U.S. nonprofit harm reduction organizations, and/or helping to increase manufacturing capacity so that more lives can be saved.
RiVive is now available for purchase!
RiVive (naloxone HCl nasal spray 3 mg) is currently available for qualifying 501(c)(3), 501(c)(4), 501(a) entities to purchase to help save lives that would have otherwise been lost due to opioid overdose.
Qualifying entities are subject to approval by Harm Reduction Therapeutics and include, but are not limited to Community Treatment Centers, EMS, Fire Departments, Public Safety Departments, Federal and State Government Agencies and other harm reduction organizations.
If you have not registered to purchase please click here
Michael R. Hufford, PhD | Co-Founder & CEO: Our Mission
We strive to save lives that would have otherwise been lost to opioid overdose by making OTC low-price naloxone available to everyone in the United States.
“We know what strategies work and what we need to do to end this epidemic.”
– Surgeon General Vivek Murthy
“No one who needs overdose reversal medications should lack access because of costs or availability.”
– White House and Office of National Drug Control Policy Director Dr. Rahul Gupta
“This crisis is killing a New Yorker every three hours and is impacting every individual and family in our city and in our nation. No one is spared, even if you think otherwise. If you use drugs, know someone who is using drugs, or might be around drug use, there are simple steps we can take. First, everyone should carry naloxone, get trained to use it and to recognize the signs of overdose…”
– New York City Health Commissioner Dr. Ashwin Vasan
“In the midst of this fentanyl overdose epidemic, it is important to focus on measures to prevent youth drug use and ensure that every school has naloxone and has prepared its students and faculty to use it.”
-U.S. Secretary of Education Miguel A. Cardona, Ed.D. and White House and Office of National Drug Control Policy Director Dr. Rahul Gupta
“Overdose reversal medications save lives, and no one should lack access because of affordability or availability.”
– Dr. Gupta
PROVEN TO SAVE LIVES
- Naloxone has been shown to be successful in reversing overdoses in 98.8% of cases.1
- The CDC reports that tens of thousands of lives have been saved since 1996.2
- A national study showed overdose deaths decreased by 14% in states that enacted naloxone access laws.3
- Statistical modeling indicates that greater naloxone availability could reduce overdose deaths by 21%.4
2. Wheeler, E., et al., Opioid Overdose Prevention Programs Providing Naloxone to Laypersons, 2014
3. McClellan, C., et al., Opioid-overdose laws association with opioid use and overdose mortality. Addictive Behaviors, 2018. 86: p. 90-95.
4. Townsend, T., et al., Cost-effectiveness analysis of alternative naloxone distribution strategies: First responder and lay distribution in the United States. International Journal of Drug Policy, 2019.